Market Place
Sourcing Support
BioMarin Presents Real-World VOXZOGO Data at ESPE Meeting
16 Nov 2024 //
PR NEWSWIRE
BioMarin to Participate in Three Upcoming Investor Conferences
06 Nov 2024 //
PR NEWSWIRE
BioMarin Reports 28% Y/Y Revenue Growth And Raises 2024 Guidance
29 Oct 2024 //
PR NEWSWIRE
BioMarin To Host Q3 2024 Financial Results Call On October 29
16 Oct 2024 //
PR NEWSWIRE
BioMarin to Present Positive VOXZOGO Data for Achondroplasia in Children
18 Sep 2024 //
PR NEWSWIRE
Ascendis` Dwarfism Drug Shows Growth Acceleration In Phase 3
18 Sep 2024 //
PRESS RELEASE
BioMarin`s Biologic Naglazyme (Galsufase) Receives Approval in US
12 Sep 2024 //
FDA
BioMarin Struggles, Terns Advances In Obesity, ESMO Creates Excitement
11 Sep 2024 //
BIOSPACE
BioMarin Plans $4B Sales By 2027 With Portfolio And Org Changes
04 Sep 2024 //
FIERCE PHARMA
Xevant and RxPreferred Expand Partnership for Innovative Pharmacy Benefits
04 Sep 2024 //
PR NEWSWIRE
BioMarin to reduce global workforce by about 225 employees
29 Aug 2024 //
REUTERS
BioMarin To Present At Morgan Stanley Healthcare Conference
29 Aug 2024 //
PR NEWSWIRE
BioMarin Brings on Roche, Amgen Alums in Executive Restructuring
22 Aug 2024 //
BIOSPACE
BioMarin Announces New R&D and Business Development Leadership
22 Aug 2024 //
PRESS RELEASE
BioMarin Scales Back Roctavian But Maintains It For 3 Key Markets
07 Aug 2024 //
FIERCE PHARMA
BioMarin Scales Back Roctavian But Maintains It For Three Key Markets
06 Aug 2024 //
FIERCE PHARMA
BioMarin Announces Updated Strategy for ROCTAVIAN® to Focus on U.S., Germany
05 Aug 2024 //
PR NEWSWIRE
BioMarin Announces 20% Y/Y Revenue Growth In Q2
05 Aug 2024 //
PR NEWSWIRE
BioMarin Biologic Brineura (Cerliponase Alfa) Receives Suppl Approvals in US
24 Jul 2024 //
FDA
BioMarin Biologic Naglazyme (Galsulfase) Receives Suppl Approvals in US
10 Jul 2024 //
FDA
BioMarin To Present VOXZOGO® Data At Children`s Bone Health Conference
17 Jun 2024 //
PR NEWSWIRE
BioMarin: 4-Year ROCTAVIAN® Safety, Efficacy Data At Hemostasis Congress
07 Jun 2024 //
PR NEWSWIRE
BioMarin confirms layoffs and R&D cuts
15 May 2024 //
LABPULSE
BioMarin sheds 170 jobs in wake of narrowed R&D refocus
15 May 2024 //
FIERCE BIOTECH
BioMarin axes 4 candidates, centers R&D around 3 assets
26 Apr 2024 //
FIERCE BIOTECH
BioMarin shares fall on slight revenue miss, despite EPS beat
24 Apr 2024 //
INVESTING
BioMarin`s Roctavian struggles continue. Is a divestment in the future?
24 Apr 2024 //
ENDPTS
BioMarin Reports Record Financial Results for the First Quarter 2024
24 Apr 2024 //
PR NEWSWIRE
BioMarin Pharmaceutical Expected to Beat Earnings Estimates: Should You Buy?
17 Apr 2024 //
YAHOO FINANCE
BioMarin Q1 2024 Results Call & Webcast on Apr 24
10 Apr 2024 //
PRESS RELEASE
Ex-BioMarin CEO Bienaimé re-emerges at Owkin
26 Mar 2024 //
PHARMAPHORUM
New Data to be Presented for BioMarin`s VOXZOGO
12 Mar 2024 //
PR NEWSWIRE
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer
07 Mar 2024 //
PR NEWSWIRE
BioMarin Scheduled to Participate in March Investor Conferences
01 Mar 2024 //
PR NEWSWIRE
BioMarin gets DOJ subpoena on sponsored testing programs for two therapies
26 Feb 2024 //
REUTERS
BioMarin Reports Record Financial Results for Fourth Quarter and Full-year 2023
22 Feb 2024 //
PRESS RELEASE
BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference
08 Feb 2024 //
PRESS RELEASE
BioMarin to Present ROCTAVIAN Data Highlighting Long-Term Durability
06 Feb 2024 //
PR NEWSWIRE
BioMarin`s chief commercial officer stepping down, search for successor begins
13 Jan 2024 //
ENDPTS
JPM24: New BioMarin CEO Hardy makes his priorities clear
10 Jan 2024 //
FIERCE PHARMA
BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
PR NEWSWIRE
BioMarin settles with Elliott, adds new directors, review committee
21 Dec 2023 //
FIERCE PHARMA
BioMarin settles with Elliott, adds 3 independent directors
20 Dec 2023 //
REUTERS
Biomarin`s Biologic Aldurazyme (laronidase) Receives Approval in the U.S.
14 Dec 2023 //
FDA
BioMarin`s Biologic Palynziq (pegvaliase) Receives Approval in the U.S.
09 Dec 2023 //
FDA
BioMarin lands 3 year deal for German coverage of gene therapy at $900K
28 Nov 2023 //
ENDPTS
Activist investor Elliott takes $1B stake in BioMarin: report
08 Nov 2023 //
FIERCE PHARMA
Genentech`s Hardy steps down, will become BioMarin CEO
02 Nov 2023 //
FIERCE PHARMA
BioMarin Announces Retirement of Jean-Jacques Bienaimé
01 Nov 2023 //
PRESS RELEASE
BioMarin Announces Strong Third Quarter 2023 Results
01 Nov 2023 //
PRESS RELEASE
The Zacks Analyst Blog Highlights Beam Therapeutics and BioMarin Pharmaceutical
27 Oct 2023 //
NASDAQ
BioMarin`s dwarfism therapy gets FDA nod for expanded use
21 Oct 2023 //
PR NEWSWIRE
BioMarin to Host Third-Quarter 2023 Financial Results Conference
17 Oct 2023 //
PRESS RELEASE
BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO
21 Sep 2023 //
PRESS RELEASE
BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO
15 Sep 2023 //
PRESS RELEASE
BioMarin looks to up pace of new drug filings
12 Sep 2023 //
FIERCE BIOTECH
